Obstetrics/Gynecology
RSSArticles
-
How Did the COVID-19 Pandemic Affect Permanent Contraception Procedures?
A national review of inpatient permanent contraception procedures between Jan. 1, 2019, and Dec. 31, 2020, demonstrated that the rate of procedures decreased in 2020 compared with 2019, with the steepest monthly decline (14.5%) being between February and April 2020, the first wave of the COVID-19 pandemic.
-
Rh Sensitization Following Induced Abortion
In this multicenter, observational, prospective cohort study, flow cytometry was used to detect circulating fetal red blood cells (fRBCs) in maternal blood among 506 participants before and after induced abortion up to 12 weeks’ gestation. Only three participants had elevated fRBCs at baseline, and only one of these had elevated fRBC counts following the abortion, which indicates that first trimester abortion is not a risk factor for Rh sensitization.
-
The Association Between BMI and Diagnosis of Endometrial Intraepithelial Neoplasia at an Early Age
In premenopausal patients, there was a linear association between increasing body mass index and decreased age at the time of endometrial intraepithelial neoplasia diagnosis.
-
Multicomponent Intervention for Early Detection and Treatment of Postpartum Hemorrhage: E-MOTIVE
This international, parallel, cluster-randomized trial assigned 80 secondary-level hospitals in four African countries to evaluate a multicomponent intervention for early detection and treatment of postpartum hemorrhage (PPH) vs. usual care following a vaginal birth. The intervention group had 60% less severe PPH cases (> 1 L blood loss) than the usual care cohort.
-
Unscheduled Bleeding with the Contraceptive Implant: Is There Any Intervention that Works?
In this randomized controlled trial of 54 patients with frequent or prolonged bleeding or spotting on the etonogestrel contraceptive implant, curcumin (the active ingredient in turmeric) was no better than placebo at controlling the total number of bleeding or spotting days during the 30-day study period.
-
Implications of Reproductive Carrier Screening During Pregnancy
About 1 in 40 females who underwent reproductive carrier screening were found to be carriers for a disease that could cause maternal symptoms during pregnancy. Healthcare providers should be aware of the potential for complications among carriers of genetic conditions during pregnancy and the best practices for handling such cases.
-
What Every OB/GYN Should Know About Cervical Cancer Prevention
This narrative review summarizes the steps of human papillomavirus (HPV)-mediated cervical carcinogenesis and uses this to explain current guidelines for HPV vaccination, cervical cancer screening, and management of abnormal results.
-
Integrating Reproductive History Could Help Postmenopausal Women’s Long-Term Brain Health
Researchers observed patients with higher cumulative estrogen exposure throughout their life may be at lower risk of developing cerebral small vessel disease.
-
CDC Recommends RSV Vaccine for Patients in Third Trimester
The agency says this solution should be administered to patients during weeks 32 through 36 of pregnancy to protect babies against the dangerous virus, both before and shortly after birth.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.